No.

Publication Date

Citing Article

1

2026

Hai Zhang, Xinyi Liu, Yunhua Zhao, Hong Fang, Yujiao Wang, Lin Chen. Selinexor as a multi-pathway regulator of the XPO1-inflammation Axis: Mechanisms, evidence in inflammatory diseases, and translational challenges, International Immunopharmacology. 2026; 187: 117185117185.  https://doi.org/10.1016/j.intimp.2026.117185

2

2026

Andrea Adrados, Juan Pérez-Fernández, Roberto García-Vicente, Alba Garrote-de-Barros, Joaquín Martinez-Lopez, María Linares, María Hernández-Sánchez. Enhancing immunotherapy efficacy in multiple myeloma and chronic lymphocytic leukemia: from combinatorial therapeutic approaches to gut microbiota modulation, Frontiers in Immunology. 2026; 17: 1805129.  https://doi.org/10.3389/fimmu.2026.1805129

3

2026

Daniel T Harding, Lara V Graham, Laura G Bartlett, Nancy Gudgeon, Jack G Fisher, Christopher J Walker, Trinayan Kashyap, Charlotte E Brookes, Aidan Haslam, Graham McIlroy, Guy Pratt, Ben M Amram, Georgia Francis, Mark S Cragg, Salim I Khakoo, Sarah Dimeloe, Matthew D Blunt. Selinexor potentiates NK cell activation against multiple myeloma, Clinical and Experimental Immunology. 2026; 220: uxag059.  https://doi.org/10.1093/cei/uxag059

4

2025

Kezia Gitareja, Shalini S. Chelliah, Elaine Sanij, Shahneen Sandhu, Jian Kang, Amit Khot. Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy, Cancers. 2025; 17: 2534.  https://doi.org/10.3390/cancers17152534

5

2025

Maria Vittoria Di Marco, Alessandro Gasparetto, Roberto Chiarle, Claudia Voena. Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer, Cells. 2025; 14: 1991.  https://doi.org/10.3390/cells14241991

6

2026

Rashidul Islam, Anne Waldhaus, Isabella Federica Bollen, Lea Descher, Amir Shalan, Valentina Alejandra Araya Balde, Annalena Liesen, Andjela Kovacevic, Gina Esther Merges, Glen Kristiansen, Hubert Schorle. 2026;   https://doi.org/10.64898/2026.09.14.750914

7

2026

Zhengchao Yan, Sijuan Tang, Chunhua Tang, Minhui He, Yuan Lin, Minxia Li, Shuang Liang, Jianbin Yang, Fangting Luo, Liwu Zhang, Jianlin Chen. 2026;   https://doi.org/10.21203/rs.3.rs-10742446/v1

8

2026

Chuanxu Liu, Dahui Li, Yan Gao, Wenhao Zhang, Zhi Guo, Jun Zhao, Huiqiang Huang, Rong Tao. Selinexor plus tislelizumab in patients with relapsed/refractory natural killer/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial, The Oncologist. 2026; 31: oyag266.  https://doi.org/10.1093/oncolo/oyag266

9

2026

Hardany PRIMARIZKY, Satoshi KAMBAYASHI, Kenji BABA, Kenji TANI, Masaru OKUDA. Combination effect of Exportin 1 inhibitor (KPT-335) with doxorubicin or vincristine in canine lymphoma cell lines, Journal of Veterinary Medical Science. 2026; 88: 25-0478119.  https://doi.org/10.1292/jvms.25-0478

10

2026

Zengli Kuang, Yu Chen, Cuiai Ren. Efficacy analysis and adverse event management of selinexor in the treatment of relapsed/refractory multiple myeloma, Frontiers in Medicine. 2026; 13: 1927209.  https://doi.org/10.3389/fmed.2026.1927209

11

2026

Seema Yadav, Anshul Shinde, Jyoti Rani, Ravindresh Chhabra. CRM1 as a potential biomarker and therapeutic target in cancer: a comprehensive review, The Nucleus. 2026;   https://doi.org/10.1007/s13237-026-00684-0

12

2026

Rushuang Xu, Xiangtao Huang, Jia Liu, Yingying Shang, Na Zhang, Jiegang Xu, Shidi Cheng, Shuangnian Xu, Xi Li. Synergistic efficacy of the EGFR inhibitor osimertinib with the XPO1 inhibitor selinexor in T-cell acute lymphoblastic leukemia, Biomarker Research. 2026; 14: 152.  https://doi.org/10.1186/s40364-026-01031-w